Comparison between virus Shedding and Fever Duration after Treating Children with Pandemic a H1N1/09 and Children with a H3N2 with a Neuraminidase Inhibitor
Free accessResearch articleFirst published online January, 2015
Comparison between virus Shedding and Fever Duration after Treating Children with Pandemic a H1N1/09 and Children with a H3N2 with a Neuraminidase Inhibitor
Shedding of the pandemic virus during an influenza pandemic is thought to persist longer than shedding of influenza viruses during annual influenza seasons, because people have much less immunity against a pandemic influenza. A correlation is thought to exist between the length of virus shedding and the clinical severity of influenza illness.
Methods
We compared the virus isolation rates of children with pandemic A H1N1/09 influenza infection and children with A H3N2 influenza infection after the patients had been treated with one of three neuraminidase inhibitors (NAI) such as peramivir, laninamivir and oseltamivir. The clinical effectiveness of each NAI was assessed on the basis of the duration of the febrile period after the start of treatment.
Results
Influenza viruses were isolated from 15 of the 34 patients in the A H3N2 group (mean age 6.2 years) and from 4 of the 25 patients in the A H1N1/09 (mean age 5.6 years) virus group (44.1% versus 16.0%; P<0.05). However, the differences between the duration of fever in the patients in the A H3N2 group and A H1N1/09 group after treatment with the NAIs were not significant.
Conclusions
The virus isolation rates after treatment with each of the NAIs were significantly lower in the A H1N1/09 group, suggesting that the pandemic A H1N1/09 virus was more sensitive to the NAIs than the seasonal A H3N2 virus was. Clinically, there were no significant differences in the effectiveness of the NAIs between the H1N1/09 infected group and H3N2 infected group.
References
1.
SugayaN., ShinjohM., MitamuraK., TakahashiT.Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children.J Infect2011; 63: 288–294.
2.
YamadaT., MorikawaM., ChoK.Pandemic (H1N1) 2009 in pregnant Japanese women in Hokkaido.J Obstet Gynaecol Res2012; 38: 130–136.
3.
SugayaN., KohnoS., IshibashiT., WajimaT., TakahashiT.Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection.Antimicrob Agents Chemother2012; 56: 369–377.
4.
KohnoS., KidaH., MizuguchiM.Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients.Antimicrob Agents Chemother2011; 55: 2803–2812.
5.
SugayaN., OhashiY.Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.Antimicrob Agents Chemother2010; 54: 2575–2582.
6.
WatanabeA., ChangS.C., KimM.J., ChuD.W., OhashiY.Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial.Clin Infect Dis2010; 51: 1167–1175.
7.
SugayaN.Widespread use of neuraminidase inhibitors in Japan.J Infect Chemother2011; 17: 595–601.
8.
HaydenF.G., FritzR., LoboM.C., AlvordW., StroberW., StrausS.E.Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense.J Clin Invest1998; 101: 643–649.
9.
YuH., LiaoQ., YuanY.Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China.BMJ2010; 341: c4779.
10.
KawaiN., IkematsuH., IwakiN.Persistence of pandemic influenza H1N1 virus in young patients after oseltamivir therapy in the 2009-2010 season: a comparison with seasonal H1N1 with or without H275Y mutation.J Infect Chemother2012; 18: 180–186.
11.
NaS., ChongY.P., KimM.N.Duration of viral shedding in patients admitted to hospital with pandemic influenza A/H1N1 2009 infection.J Med Virol2011; 83: 5–9.
12.
LingL.M., ChowA.L., LyeD.C.Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection.Clin Infect Dis2010; 50: 963–969.
13.
ChinB.S., ChaeY.T., ChoiH.K.Viral shedding of 2009 pandemic H1N1 and evaluation of quarantine recommendations.Jpn J Infect Dis2012; 65: 105–110.
14.
SugayaN., MitamuraK., YamazakiM.Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children.Clin Infect Dis2007; 44: 197–202.
15.
HatakeyamaS., Sakai-TagawaY., KisoM.Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor.J Clin Microbiol2005; 43: 4139–4146.
16.
FuruseY., OdagiriT., OkadaT.Differentiation of human influenza A viruses including the pandemic subtype H1N1/2009 by conventional multiplex PCR.J Virol Methods2010; 168: 94–97.
17.
The R Project for Statistical Computing.A language and environment for statistical computing, 2012. (Accessed 7 December 2013.) Available from http://www.R-project.org/.
18.
KisoM., MitamuraK., Sakai-TagawaY.Resistant influenza A viruses in children treated with oseltamivir: descriptive study.Lancet2004; 364: 759–765.
19.
Centers for Disease Control and Prevention.Update: influenza activity - United States, 2009-10 season.MMWR Morb Mortal Wkly Rep2010; 59: 901–908.
20.
SuzukiY., SaitoR., SatoI.Identification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe method.J Clin Microbiol2011; 49: 125–130.
21.
LouieJ.K., YangS., AcostaM.Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09.Clin Infect Dis2012; 55: 1198–1204.
22.
MuthuriS.G., MylesP.R., VenkatesanS., Leonardi-BeeJ., Nguyen-Van-TamJ.S.Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients.J Infect Dis2013; 207: 553–563.
23.
ShobugawaY., SaitoR., SatoI.Clinical effectiveness of neuraminidase inhibitors-oseltamivir, zanamivir, laninamivir, and peramivir-for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.J Infect Chemother2012; 18: 858–864.
24.
SugayaN., TamuraD., YamazakiM.Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children.Clin Infect Dis2008; 47: 339–345.
